The targeting of the MDM2/MDMX axis represents a promising strategy to reactivate the P53 pathway in cancer cells overexpressing MDM2/MDMX, thus offering a novel avenue for current cancer therapeutics (Corney et al., 2008). Here, TP53 is linked to cancer.